FDA approves first-in-class hypertension drug from AstraZeneca
The pivotal trial for baxdrostat showed nearly double-digit placebo-adjusted systolic blood pressure reduction.
The pivotal trial for baxdrostat showed nearly double-digit placebo-adjusted systolic blood pressure reduction.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
